Actelion Ltd (ALIOF) 112.2900 $ALIOF
Synthetic Biologics Unveils Phase Ib Safety Data on SYN-004 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 12:30PM CST
Synthetic Biologics, Inc. (SYN) announced positive top-line results from phase Ib study on SYN-004.
SYN: 2.13 (+0.18), BMRN: 100.76 (+1.98), ALNY: 95.54 (+1.67)
Arena Pharmaceuticals Doses for Cardiovascular Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 16, 1:20PM CST
Arena Pharmaceuticals, Inc. (ARNA) recently announced that it has initiated patient dosing in a phase II clinical trial on pipeline candidate, ralinepag.
UTHR: 151.11 (+3.59), ARNA: 4.55 (+0.02), RGDO: 1.17 (+0.02)
Actelion to present at the 33rd J.P. Morgan Healthcare Conference - Transforming our PAH portfolio
Thomson Reuters ONE - Mon Jan 12, 12:00AM CST
Actelion Pharmaceuticals Ltd / Actelion to present at the 33rd J.P. Morgan Healthcare Conference - Transforming our PAH portfolio . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
JPM: 59.67 (+0.10)
Arena autoimmune disease candidate successful in Phase 1b
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 9:41AM CST
GSK: 47.94 (+1.99), ARNA: 4.55 (+0.02)
United Therapeutics - DEKA Ink Deal for Remodulin System - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 4:00PM CST
United Therapeutics (UTHR) inked a deal with DEKA for the development of a pre-filled semi-disposable pump system for the subcutaneous delivery of Remodulin injection in pulmonary arterial hypertension patients.
CBST: 101.94 (+0.14), MDT: 75.26 (+0.33), UTHR: 151.11 (+3.59)
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/2n69ld/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects Scope - The report provides a snapshot of the global therapeutic landscape of Relapsing Remitting Multiple Sclerosis (RRMS) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsing Remitting Multiple Sclerosis (RRMS) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Relapsing Remitting Multiple Sclerosis (RRMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - MedImmune, LLC - XenoPort, Inc. - Novartis AG - Actelion Ltd - Mitsubishi Tanabe Pharma Corporation - Octapharma AG - Teva Pharmaceutical Industries Limited - Genmab A/S - Merck KGaA - Antisense Therapeutics Limited - Opexa Therapeutics - Trophos SA - Allozyne - Amarna Therapeutics - Synthetic Biologics - Cognosci - RedHill Biopharm - Nuron Biotech - Neurotec Pharma SL - BIOCAD - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/2n69ld/relapsing
GSK: 47.94 (+1.99), XNPT: 6.69 (-0.21), OPXA: 0.71 (-0.03), SYN: 2.13 (+0.18), ABBV: 58.05 (+1.00), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Synthetic Biologics Commences Phase Ib Study on SYN-004 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 1:40PM CST
Synthetic Biologics, Inc. (SYN) announced the commencement and dosing of the first patient in a phase Ib study on its oral investigational candidate, SYN-004.
SYN: 2.13 (+0.18), MDCO: 29.79 (+0.91), RGDO: 1.17 (+0.02)
Synthetic Biologics Unveils Top-Line Safety Data on SYN-004 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 29, 4:40PM CST
Synthetic Biologics, Inc. (SYN) announced positive results from the first safety and tolerability review in a phase Ia study on its investigational candidate, SYN-004.
SYN: 2.13 (+0.18), MDCO: 29.79 (+0.91), AMGN: 153.48 (+0.30)
Actelion Submits New Drug Application for Uptravi in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 4:35PM CST
Actelion Ltd. (ALIOF) announced the submission of a new drug application to the FDA for its pulmonary arterial hypertension candidate, Uptravi (selexipag).
ANIP: 62.69 (-0.43), UTHR: 151.11 (+3.59)
Actelion submits US FDA New Drug Application for selexipag (Uptravi) in patients with pulmonary arterial hypertension
Thomson Reuters ONE - Mon Dec 22, 5:01PM CST
Actelion Pharmaceuticals Ltd / Actelion submits US FDA New Drug Application for selexipag (Uptravi) in patients with pulmonary arterial hypertension . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Malaria - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/d6q6fd/malaria) has announced the addition of the "Malaria - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malaria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malaria and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - Genzyme Corporation - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - GenVec, Inc. - Takeda Pharmaceutical Company Limited - Imaxio - FIT Biotech Oyj - Novartis AG - Actelion Ltd - Chong Kun Dang Pharmaceutical Corp. - Eisai Co., Ltd. - Pfizer Inc. - Ranbaxy Laboratories Limited - Sigma-Tau S.p.A. - Aduro BioTech, Inc. - CEL-SCI Corporation - Crucell N.V. - Immtech Pharmaceuticals, Inc. - Mymetics Corporation - Patrys Limited - IPCA Laboratories Limited - Xenetic Biosciences plc - Raptor Pharmaceuticals Corp. - Affitech A/S - D-Pharm Ltd. - Colby Pharmaceutical Company - Bharat Biotech International Limited - Jenrin Discovery, Inc. - Mucosis B.V. - Protein Potential, LLC - Amura Holdings Ltd. - Anacor Pharmaceuticals, Inc. - Telormedix SA - Grupo Ferrer Internacional, S.A. - Chimerix, Inc. - Sanaria Inc. - NovaLead Pharma Pvt. Ltd. - Acetylon Pharmaceuticals, Inc. - Etubics Corporation - iBio, Inc. - Seek - Cellceutix Corporation - Genocea Biosciences, Inc. - Hawaii Biotech, Inc. - iQur Ltd. - Rodos BioTarget GmbH - Sigma-Tau Pharmaceuticals, Inc - Selecta Biosciences, Inc. - Artificial Cell Technologies, Inc. - Pfenex Inc. - NeED Pharma s.r.l. - VLP Biotech, Inc. - Jomaa Pharma GmbH - DesignMedix, Inc. - Conkwest, Inc. - Panacela Labs, Inc. - Dilaforette AB - Agilvax, Inc. - LondonPharma Ltd - GlobalAcorn For more information visit http://www.researchandmarkets.com/research/d6q6fd/malaria
CVM: 0.84 (-0.01), PFNX: 12.45 (+0.29), INO: 6.80 (-0.15), CMRX: 40.16 (+0.08), RPTP: 9.05 (-0.40), IBIO: 0.90 (+0.36), ANAC: 40.76 (-0.07), PFE: 34.64 (-0.23), GNCA: 8.93 (-0.07), GSK: 47.94 (+1.99), AZN: 69.96 (+0.20), NVS: 102.20 (-0.17)
Actelion submits MAA for pulmonary hypertension drug
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 2:36PM CST
MSTX: 0.47 (+0.01), GILD: 101.90 (+1.10), UTHR: 151.11 (+3.59), GSK: 47.94 (+1.99), ARNA: 4.55 (+0.02)
Actelion Submits Marketing Application for Uptravi in EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 2:10PM CST
Actelion Ltd. (ALIOF) submitted a centralized marketing authorization application to the European Medicines Agency for its PAH candidate, Uptravi (selexipag).
BIIB: 391.66 (-0.45), UTHR: 151.11 (+3.59)
Actelion submits selexipag (Uptravi) for EMA Marketing Authorisation in patients with pulmonary arterial hypertension
Thomson Reuters ONE - Mon Dec 01, 5:00PM CST
Actelion Pharmaceuticals Ltd / Actelion submits selexipag (Uptravi) for EMA Marketing Authorisation in patients with pulmonary arterial hypertension . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Cempra Poised To Join Antibacterial Drug Acquisition Buzz With Upcoming Data Release
StockMatusow - at Seeking Alpha - Tue Nov 25, 7:00AM CST
TTPH: 35.18 (-0.73), CBST: 101.94 (+0.14), ROG: 81.63 (+2.37), CEMP: 27.68 (+1.25)
Tetraphase mulling selling itself
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 7:40AM CST
JNJ: 99.62 (+1.18), TTPH: 35.18 (-0.73), MRK: 58.81 (-0.07)
Research and Markets: Mycosis Fungoides Therapeutics Pipeline Review, H2 2014 Report Featuring Sanofi, Seattle Genetics, Inc, Echo Therapeutics, Inc. & Actelion Ltd
Business Wire - Thu Nov 06, 4:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/mlg9h9/mycosis_fungoides) has announced the addition of the "Mycosis Fungoides - Pipeline Review, H2 2014" report to their offering.
ECTE: 2.62 (+0.06), SGEN: 31.57 (+0.36)
Mycosis Fungoides Therapeutics Pipeline Review, H2 2014 Report Featuring Sanofi, Seattle Genetics, Inc, Echo Therapeutics, Inc. & Actelion Ltd
M2 - Thu Nov 06, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/n96mgn/mycosis_fungoides) has announced the addition of the "Mycosis Fungoides - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Mycosis Fungoides, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mycosis Fungoides and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - Seattle Genetics, Inc. - Echo Therapeutics, Inc. - Actelion Ltd Drug Profiles - brentuximab vedotin - mechlorethamine hydrochloride - alemtuzumab - methotrexate - NSC-678515 - CIGB-128 For more information visit http://www.researchandmarkets.com/research/n9..._fungoides
ECTE: 2.62 (+0.06), SGEN: 31.57 (+0.36)
Actelion Misses Q3 Earnings Expectation, Ups 2014 Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 10:40AM CDT
Actelion Ltd. (ALIOF) reported third-quarter earnings of $1.36 per American Depository Receipt (ADR), but below the Zacks Consensus Estimate of $1.50 per share.
MDVN: 104.71 (+0.67), HALO: 14.73 (+0.23), LGND: 55.91 (-0.35)
Actelion delivers strong nine months results
Thomson Reuters ONE - Tue Oct 21, 12:00AM CDT
Actelion Pharmaceuticals Ltd / Actelion delivers strong nine months results . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Synthetic Biologics Unveils Phase Ib Safety Data on SYN-004 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 12:30PM CST
Synthetic Biologics, Inc. (SYN) announced positive top-line results from phase Ib study on SYN-004.
SYN: 2.13 (+0.18), BMRN: 100.76 (+1.98), ALNY: 95.54 (+1.67)
Arena Pharmaceuticals Doses for Cardiovascular Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 16, 1:20PM CST
Arena Pharmaceuticals, Inc. (ARNA) recently announced that it has initiated patient dosing in a phase II clinical trial on pipeline candidate, ralinepag.
UTHR: 151.11 (+3.59), ARNA: 4.55 (+0.02), RGDO: 1.17 (+0.02)
Actelion to present at the 33rd J.P. Morgan Healthcare Conference - Transforming our PAH portfolio
Thomson Reuters ONE - Mon Jan 12, 12:00AM CST
Actelion Pharmaceuticals Ltd / Actelion to present at the 33rd J.P. Morgan Healthcare Conference - Transforming our PAH portfolio . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
JPM: 59.67 (+0.10)
Arena autoimmune disease candidate successful in Phase 1b
Seeking Alpha - at Seeking Alpha - Wed Jan 07, 9:41AM CST
GSK: 47.94 (+1.99), ARNA: 4.55 (+0.02)
United Therapeutics - DEKA Ink Deal for Remodulin System - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 4:00PM CST
United Therapeutics (UTHR) inked a deal with DEKA for the development of a pre-filled semi-disposable pump system for the subcutaneous delivery of Remodulin injection in pulmonary arterial hypertension patients.
CBST: 101.94 (+0.14), MDT: 75.26 (+0.33), UTHR: 151.11 (+3.59)
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/2n69ld/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects Scope - The report provides a snapshot of the global therapeutic landscape of Relapsing Remitting Multiple Sclerosis (RRMS) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsing Remitting Multiple Sclerosis (RRMS) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Relapsing Remitting Multiple Sclerosis (RRMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - MedImmune, LLC - XenoPort, Inc. - Novartis AG - Actelion Ltd - Mitsubishi Tanabe Pharma Corporation - Octapharma AG - Teva Pharmaceutical Industries Limited - Genmab A/S - Merck KGaA - Antisense Therapeutics Limited - Opexa Therapeutics - Trophos SA - Allozyne - Amarna Therapeutics - Synthetic Biologics - Cognosci - RedHill Biopharm - Nuron Biotech - Neurotec Pharma SL - BIOCAD - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/2n69ld/relapsing
GSK: 47.94 (+1.99), XNPT: 6.69 (-0.21), OPXA: 0.71 (-0.03), SYN: 2.13 (+0.18), ABBV: 58.05 (+1.00), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Synthetic Biologics Commences Phase Ib Study on SYN-004 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 1:40PM CST
Synthetic Biologics, Inc. (SYN) announced the commencement and dosing of the first patient in a phase Ib study on its oral investigational candidate, SYN-004.
SYN: 2.13 (+0.18), MDCO: 29.79 (+0.91), RGDO: 1.17 (+0.02)
Synthetic Biologics Unveils Top-Line Safety Data on SYN-004 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 29, 4:40PM CST
Synthetic Biologics, Inc. (SYN) announced positive results from the first safety and tolerability review in a phase Ia study on its investigational candidate, SYN-004.
SYN: 2.13 (+0.18), MDCO: 29.79 (+0.91), AMGN: 153.48 (+0.30)
Actelion Submits New Drug Application for Uptravi in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 4:35PM CST
Actelion Ltd. (ALIOF) announced the submission of a new drug application to the FDA for its pulmonary arterial hypertension candidate, Uptravi (selexipag).
ANIP: 62.69 (-0.43), UTHR: 151.11 (+3.59)
Actelion submits US FDA New Drug Application for selexipag (Uptravi) in patients with pulmonary arterial hypertension
Thomson Reuters ONE - Mon Dec 22, 5:01PM CST
Actelion Pharmaceuticals Ltd / Actelion submits US FDA New Drug Application for selexipag (Uptravi) in patients with pulmonary arterial hypertension . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Malaria - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/d6q6fd/malaria) has announced the addition of the "Malaria - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malaria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malaria and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - Genzyme Corporation - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - GenVec, Inc. - Takeda Pharmaceutical Company Limited - Imaxio - FIT Biotech Oyj - Novartis AG - Actelion Ltd - Chong Kun Dang Pharmaceutical Corp. - Eisai Co., Ltd. - Pfizer Inc. - Ranbaxy Laboratories Limited - Sigma-Tau S.p.A. - Aduro BioTech, Inc. - CEL-SCI Corporation - Crucell N.V. - Immtech Pharmaceuticals, Inc. - Mymetics Corporation - Patrys Limited - IPCA Laboratories Limited - Xenetic Biosciences plc - Raptor Pharmaceuticals Corp. - Affitech A/S - D-Pharm Ltd. - Colby Pharmaceutical Company - Bharat Biotech International Limited - Jenrin Discovery, Inc. - Mucosis B.V. - Protein Potential, LLC - Amura Holdings Ltd. - Anacor Pharmaceuticals, Inc. - Telormedix SA - Grupo Ferrer Internacional, S.A. - Chimerix, Inc. - Sanaria Inc. - NovaLead Pharma Pvt. Ltd. - Acetylon Pharmaceuticals, Inc. - Etubics Corporation - iBio, Inc. - Seek - Cellceutix Corporation - Genocea Biosciences, Inc. - Hawaii Biotech, Inc. - iQur Ltd. - Rodos BioTarget GmbH - Sigma-Tau Pharmaceuticals, Inc - Selecta Biosciences, Inc. - Artificial Cell Technologies, Inc. - Pfenex Inc. - NeED Pharma s.r.l. - VLP Biotech, Inc. - Jomaa Pharma GmbH - DesignMedix, Inc. - Conkwest, Inc. - Panacela Labs, Inc. - Dilaforette AB - Agilvax, Inc. - LondonPharma Ltd - GlobalAcorn For more information visit http://www.researchandmarkets.com/research/d6q6fd/malaria
CVM: 0.84 (-0.01), PFNX: 12.45 (+0.29), INO: 6.80 (-0.15), CMRX: 40.16 (+0.08), RPTP: 9.05 (-0.40), IBIO: 0.90 (+0.36), ANAC: 40.76 (-0.07), PFE: 34.64 (-0.23), GNCA: 8.93 (-0.07), GSK: 47.94 (+1.99), AZN: 69.96 (+0.20), NVS: 102.20 (-0.17)
Actelion submits MAA for pulmonary hypertension drug
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 2:36PM CST
MSTX: 0.47 (+0.01), GILD: 101.90 (+1.10), UTHR: 151.11 (+3.59), GSK: 47.94 (+1.99), ARNA: 4.55 (+0.02)
Actelion Submits Marketing Application for Uptravi in EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 2:10PM CST
Actelion Ltd. (ALIOF) submitted a centralized marketing authorization application to the European Medicines Agency for its PAH candidate, Uptravi (selexipag).
BIIB: 391.66 (-0.45), UTHR: 151.11 (+3.59)
Actelion submits selexipag (Uptravi) for EMA Marketing Authorisation in patients with pulmonary arterial hypertension
Thomson Reuters ONE - Mon Dec 01, 5:00PM CST
Actelion Pharmaceuticals Ltd / Actelion submits selexipag (Uptravi) for EMA Marketing Authorisation in patients with pulmonary arterial hypertension . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Cempra Poised To Join Antibacterial Drug Acquisition Buzz With Upcoming Data Release
StockMatusow - at Seeking Alpha - Tue Nov 25, 7:00AM CST
TTPH: 35.18 (-0.73), CBST: 101.94 (+0.14), ROG: 81.63 (+2.37), CEMP: 27.68 (+1.25)
Tetraphase mulling selling itself
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 7:40AM CST
JNJ: 99.62 (+1.18), TTPH: 35.18 (-0.73), MRK: 58.81 (-0.07)
Research and Markets: Mycosis Fungoides Therapeutics Pipeline Review, H2 2014 Report Featuring Sanofi, Seattle Genetics, Inc, Echo Therapeutics, Inc. & Actelion Ltd
Business Wire - Thu Nov 06, 4:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/mlg9h9/mycosis_fungoides) has announced the addition of the "Mycosis Fungoides - Pipeline Review, H2 2014" report to their offering.
ECTE: 2.62 (+0.06), SGEN: 31.57 (+0.36)
Mycosis Fungoides Therapeutics Pipeline Review, H2 2014 Report Featuring Sanofi, Seattle Genetics, Inc, Echo Therapeutics, Inc. & Actelion Ltd
M2 - Thu Nov 06, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/n96mgn/mycosis_fungoides) has announced the addition of the "Mycosis Fungoides - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Mycosis Fungoides, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mycosis Fungoides and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - Seattle Genetics, Inc. - Echo Therapeutics, Inc. - Actelion Ltd Drug Profiles - brentuximab vedotin - mechlorethamine hydrochloride - alemtuzumab - methotrexate - NSC-678515 - CIGB-128 For more information visit http://www.researchandmarkets.com/research/n9..._fungoides
ECTE: 2.62 (+0.06), SGEN: 31.57 (+0.36)
Actelion Misses Q3 Earnings Expectation, Ups 2014 Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 10:40AM CDT
Actelion Ltd. (ALIOF) reported third-quarter earnings of $1.36 per American Depository Receipt (ADR), but below the Zacks Consensus Estimate of $1.50 per share.
MDVN: 104.71 (+0.67), HALO: 14.73 (+0.23), LGND: 55.91 (-0.35)
Actelion delivers strong nine months results
Thomson Reuters ONE - Tue Oct 21, 12:00AM CDT
Actelion Pharmaceuticals Ltd / Actelion delivers strong nine months results . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
